HOME
ABOUT THE COMPANY
Company Overview
Message from CEO
Management Team
Enterprise Video
INNOVATION
Pipeline
Focus Areas
Pipeline2
INVESTORS
Fact Sheet
Corporate Governance
Public Disclosure
Financial Report
Announcements and Circulars
Presentations and Webcasts
IR Contact
Analyst List
MEDIA
CONTACT
Contact
Career
菜单
中文
|
EN
HOME
ABOUT THE COMPANY
Company Overview
Message from CEO
Management Team
Enterprise Video
Innovation
Innovation
Pipeline
Focus Areas
Pipeline2
INVESTORS
Fact Sheet
Corporate Governance
Financial Report
Announcements and Circulars
Presentations and Webcasts
Analyst List
IR Contact
MEDIA
CONTACT
Contact
Career
中欧体育提示
本内容仅供医学专业人士使用。如果您是医学专业人士,请点击确认,进入页面;否则请点击退出,返回上一页。
确定
取消
Home
/
Media
Press Release
Media Report
2018
2022
2021
2020
2019
2018
2018-12-17
Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese market
2018-11-05
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region
Follow us